Posted by Site Administrator on October 4, 2012
South San Francisco biotechnology company Cytokinetics announced Sept. 10, 2012, that it plans to conduct a new phase 2b clinical trial of its oral drug tirasemtiv (formerly CK-2017357) in people with amyotrophic lateral sclerosis (ALS). The trial is set to launch later this year.
Categories: Clinical Trials, Research News, Treatments
| 
Tags: ALS, ALS community, ALS research, ALS treatments, amyotrophic lateral sclerosis, Andrew A. Wolff, CK-2017357, Cytokinetics, FDA ALS, Lou Gehrig's disease, PALS, phase 2b clinical trial tirasemtiv, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Tirasemtiv
| 
No comments
Posted by Site Administrator on June 19, 2012
Both patients and investigators perceived a dose-dependent benefit of CK-2017357 as measured by global impression of change. Maximum voluntary ventilation and submaximal handgrip endurance also improved.
Categories: Research News, Treatments
| Tags: ALS, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, Andrew A. Wolff, Bob Stehlin, CK-2017357, Clinical Trial Publication of CK-2017357 in Amyotrophic Lateral Sclerosis, CY 4025, Cytokinetics, fast skeletal muscle troponin activator, FDA Fast Track designation ALS, Jeremy M. Shefner, Phase II, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Upstate Medical University at the State University of New York
| No comments
